Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes
Mandate

Vinge advised Nalka Strukturfond AB in connection with the acquisition of Cibes

June 13, 2017 Banking and Finance

Vinge has advised Nalka Strukturfond AB in connection with the acquisition of CL Intressenter AB (”Cibes”) from R12 Kapital Fund I AB as well as a number of minority owners.

Cibes is a leading manufacturer of platform lifts with its base in Gävle and with global operations. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consisted of responsible partner Jonas Johansson and partner Peter Sundgren together with, among others, associates Johan Mattsson, Peter Issa, Andrea Ahlgren, Lova Unge, Jasmin Draszka Ali, Frida Ställborn, Ilze Lukins, Lionardo Ojeda, Fredrika Hjelmberg, Martin Boström, Grant McKelvey and Xandra Ståhlberg as well as senior counsel Qun Gu and VDR specialist Anna Hellohf. Partner Louise Brorsson Salomon together with associate Helena Håkansson provided acquisition financing advice.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025